Biodesix, Inc.(BDSX)Earnings, Financials & Key RatiosBiodesix, Inc. (BDSX) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's reliance on external funding is underscored by a $10.3M quarterly free cash flow burn and a precarious debt-to-equity ratio of 7.84, which suggests significant dilution risk for shareholders.
Biodesix, Inc. (BDSX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Biodesix, Inc. (BDSX) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 4, 2026 | $0.81vs $1.26+35.7% | $26Mvs $23M+10.5% |
| Q1 2026 | Feb 26, 2026 | $0.49vs $1.05+53.3% | $29Mvs $26M+11.8% |
| Q4 2025 | Nov 3, 2025 | $1.16vs $1.60+27.5% | $22Mvs $26M-17.1% |
| Q3 2025 | Aug 7, 2025 | $1.60vs $1.40-14.3% | $20Mvs $18M+8.4% |
Recent stock market news and headlines for Biodesix, Inc. (BDSX)
Biodesix (BDSX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Key metrics vs top competitors for Biodesix, Inc. (BDSX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $20.34 | $153.59M | -4.36 | 24.08% | -39.85% | -383.09% | — | |
| $104.91 | $20.02B | -95.37 | 17.69% | -6.4% | -8.66% | — | |
| $281.27 | $40.28B | -185.05 | 35.9% | -9.05% | -15.13% | — | |
| $56.16 | $4.48B | 68.49 | 16.01% | 16.25% | 6.86% | — | |
| $1.07 | $672.52K | -0.23 | -67.7% | -1319.55% | -105.46% | — | |
| $191.76 | $29.13B | 35.19 | -0.78% | 19.43% | 32.84% | — |
Biodesix, Inc. (BDSX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Biodesix, Inc. (BDSX) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 4, 2026·SEC
Feb 26, 2026·SEC
Nov 3, 2025·SEC
Get notified when BDSX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Biodesix, Inc. (BDSX) stock FAQ — growth, dividends, profitability & financials explained
Biodesix, Inc. (BDSX) reported $96.1M in revenue for fiscal year 2025. This represents a 370% increase from $20.4M in 2018.
Biodesix, Inc. (BDSX) grew revenue by 24.1% over the past year. This is strong growth.
Biodesix, Inc. (BDSX) reported a net loss of $32.0M for fiscal year 2025.
Biodesix, Inc. (BDSX) has a return on equity (ROE) of -383.1%. Negative ROE indicates the company is unprofitable.
Biodesix, Inc. (BDSX) had negative free cash flow of $25.2M in fiscal year 2025, likely due to heavy capital investments.
